Usona secured FDA priority voucher for its psilocybin candidate PSIL201
The race to win the first FDA nod for a classic psychedelic is intensifying, with Usona Institute reportedly filing for approval ahead of the field leader Compass Pathways.
- Field
- drugs and trials
- What they did
- Researchers at Usona Institute launched phase III clinical trials for their psilocybin-based drug to treat treatment-resistant depression and secured an expedited review from the FDA.
- Why it matters
- This could change the market for psychedelic drugs, as Usona, a company previously low-profile, might become the first to receive FDA approval for a classic psychedelic.
#psilocybin#fda#usona institute#depression#clinical trial



